Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLD-0915 in Metastatic Prostate Cancer
NCT06800313Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Aug 2028
- Modality
- Molecular Glues
- Countries
- 2
01
Overview
A Phase 2 trial of HLD-0915 in Metastatic Prostate Cancer (mPC), sponsored by Janssen Pharmaceutical. Started Feb 2025; status: recruiting.
02
Drugs
HLD-0915
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT06800313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06800313.